Myosin ATPase inhibitors are being developed for the treatment of cardiomyopathy caused by similar mutations of cardiac myosin heavy chain genes (Green et al, 2016); therefore, we sought to determine whether drugs that directly inhibit function of myosin (Kovács et al, 2004) could reduce the adverse phenotypic effects of the smyhc1R673H allele. Here, MYH14 is linked to cardiomyopathy.